INTRODUCTION
Platelets are circulating blood cells primarily involved in hemostatic and thrombotic functions (1, 2) . Disorders of platelet function may predispose to bleeding or to thrombotic and atherosclerotic disorders (3, 4) . Understanding of the biology of this cell has been facilitated by careful study of congenital abnormalities of platelets as in thrombasthenia, a deficiency of platelet surface glycoproteins (5) (6) (7) , and the HermanskyPudlak syndrome or storage pool deficiency in which a selective absence of platelet-dense granules occurs (8) (9) (10) (11) . These natural experiments provide important clues to the role of the missing structures in cellular physiology. The gray platelet syndrome, first described by Raccuglia in 1971 (12) , is a disorder characterized by large platelets that contain few granules and, therefore, appear gray when viewed under the light microscope, the characteristic that gives the disorder its name. Electron microscopic studies of this disorder have revealed a relative deficiency of a-granules, and normal numbers of dense bodies and peroxisomes in these platelets (3, (12) (13) (14) . We now report an evaluation of the biochemistry of these platelets, including analysis of adenine nucleotides and serotonin constituents of platelet-dense bodies, hydrolytic enzymes present in platelet lysosomes, catalase believed to be in the platelet peroxisomes, and various polypeptides present in a-granules. The selective absence of agranules and their contents in this disorder provides a new approach to subcellular localization of certain platelet proteins, and provides a natural experiment to probe the role of a-granules in platelet function.
METHODS
Patients. Two patients with the gray platelet syndrome were studied. The first was a 22 yr-old male originally described by Raccuglia (12) . This patient had petechiae and ecchymoses as a newborn and a bruising tendency with recurrent knee pain, presumably intraarticular bleeding, throughout childhood. His platelet count during this period ranged from 25,000-150,000/mm3. It increased temporarily on two occasions after prednisone and permanently after splenectomy at age nine, though it has been slightly below normal in the last few years (range 100,000-150,000/mm3). He has had only one severe bleeding episode (a large hematoma) since then, after a football injury, although his bleeding times have remained slightly longer than normal. The second patient studied was a girl with Goldenhar's syndrome (oculoauriculovertebral dysplasia). She developed a recurrent petechial rash associated with frequent bruises at about 8 mo of age, a time when she was frequently falling in her efforts to learn to walk. This bruising tendency continued. About 2 yr of age she developed a large black eye after her face had been hit lightly. She was then referred for evaluation and found to have large gray platelets on a Wright stained blood smear. This patient is now age four. She has continued to have a bruising tendency, and on one occasion, after a small laceration to one toe, she bled for a "long time" before it stopped. Her platelet count has ranged between 100,000 and 150,000/mm3.
Experimental. For most experiments, blood drawn from the antecubital vein from patients or normal donors was anticoagulated with citrate-citric acid dextrose, pH 6.5, to achieve final concentrations of 9.3 mM sodium citrate, 0.7 mM citric acid, and 14 mM dextrose. For study of platelet polypeptides and surface glycoproteins, 17.2 ml of blood was drawn from each normal donor and each patient and mixed with 2.8 ml of acid citrate dextrose (15) . The blood was then centrifuged immediately at 100 g for 20 min at room temperature to obtain platelet-rich plasma. Platelet aggregation studies were performed using a Payton dual channel aggregometer (Payton Associates, Buffalo, N. Y.) as described previously (16) . Samples for study of platelet ultrastructure were fixed, embedded, sectioned, stained, and viewed under a Phillips 301 electron microscope (Philips Co., Mount Vernon, N. Y.) as described previously (17) . Quantitative morphometry of platelets was performed on randomly sampled electron micrographs (x30,000) using an overlain grid of intersecting lines 0.6 cm apart. Point counts of structures beneath intersects were performed to evaluate the contribution of various platelet structures to total platelet volume (18) . For each sample, 1,200-1,500 intersects representing 30-50 platelets were counted. Analysis of platelet size was performed using a Coulter counter model ZB channelyzer C-1000 (Coulter Electronics Inc., Hialeah, Fla.) (19) . Platelet serotonin levels were measured spectrophotofluorometrically (20) . Platelet adenine nucleotides were measured using high pressure liquid chromatography (21) . Platelet fibrinogen was measured on gel-filtered platelets by radioimmunoassay (22, 23) . Catalase and lysosomal enzymes were measured using standard assays (24, 25) . The conversion of arachidonic acid by washed platelets was assessed after stirring of the cells with the fatty acid for 5 min, using both quantitative gas chromatography mass spectrometry, and by assessing conversion of labeled [I4C]arachidonic acid, using thin layer chromatographic separation of products as described earlier (26) .
Platelet-derived growth factor was assayed using fibroblast 3T3 cells as described previously (27, 28) . To release the platelet-derived growth factor from the platelets, the cells were frozen-thawed three times, the homogenate centrifuged at 16,000 rpm in a Sorvall SS-34 rotor (DuPont InstrumentsSorvall Biomedical Div., DuPont Co., Newtown, Conn.) for 30 min, the pellet resuspended in 1.09 M NaCl, 0.01 M Tris, pH 7.4, and spun again for 30 min using the same conditions. The combined supernates were dialyzed against phosphatebuffered saline for 24 h. The frozen-thawed supernate was equivalent to 0.34 x 109 platelets/ml, and the salt extract equivalent to 0.70 x 109 platelets/ml.
Platelet factor 4 (PF4)1 and f-thromboglobulin were measured by radioimmunoassay. The procedure used in Lab B for both PF4 and P-thromboglobulin has been described elsewhere (29) . The assay for PF4 used in Lab A involved its purification according to the procedure of Hermondson et al. (30) , then preparation of antisera by injecting 3-kg New Zealand white rabbits with 1 mg purified protein mixed with complete Freund's adjuvant. Serum, collected after antibody was demonstrated by a precipitin line on agar gel electrophoresis, was stored in 0.3-ml aliquots in a -70°freezer. For the radioimmunoassay, the PF4 was labeled using lactoperoxidase, by combining 10 ,g of purified PF4 with 1 mCi of '25I in 40 ,ul of 0.4 M Na acetate. 10 ,lA of H202 (-3 x 10-6g) was added to the mixture for 5 min at room temperature, after which an additional 5 ,ul of H202 was added. At 8 min total time, the reaction mixture was run over a heparin agarose column and washed with phosphate-buffered saline, pH 6.4, to remove the unbound '25I and to stop the lactoperoxidase reaction. When the eluate had <1,000 cpm/10 1,u, the '2I-PF4 was eluted with 2 M NaCl and collected in 0.5-ml fractions in plastic tubes coated with 0.2% bovine serum albumin. The '25I-PF4 had about 6 x 107 counts/4g. The labeled fraction with the greatest activity was used in the assay after dilution with standard buffer to give 20,000 cpm/20 ,ul and stored at -70°. '25I-PF4 was stable for 3-4 mo.
For the radioimmunoassay itself, standard unlabeled PF4 was diluted in buffer (0.1 M Tris, 0.15 M NaCl, 0.2% Na azide, 0.5 U heparin/ml, and 2% dog plasma) to the PF4 concentrations in the standard curve that included 10 ng, 3 ng, 1 ng, 300 pg, 100 pg, 30 pg, and 10 pg. A zero point, representing maximal precipitation of 1251-PF4 by antibody with no added PF4, was also included in the standard curve. The antibody, diluted 20,000-40,000-fold in buffer, gave -50% binding of the "251-PF4. Excess antibody bound 95% of the labeled PF4.
The assay was then performed in triplicate as follows: 300 ,ul of diluted antihuman PF4 antibody was mixed with 100 ,ul of PF4 standard or 100 ,l of patient sample, to which 20 Al of radiolabeled PF4 (20,000 cpm) was added. This combination was mixed and incubated overnight at room temperature. Then 50 ,ul of goat antirabbit immunoglobulin (Ig)G in 0.9% saline and 100 ,ul of carrier rabbit IgG (0.1 mg) in 0.9% saline were added, mixed, incubated for 2 h, after which 1 ml of 0.01 M Tris, 0.15 M NaCl was added. The tubes were centrifuged at 7,000 g for 20 min. The unbound '25I-PF4 in the supernate was decanted and the precipitate counted. Samples for determination of serum levels were prepared by dilution of serum with standard buffer. The 1:500 and 1:1,000 dilutions were placed in the assay and the results of the two dilutions averaged for the final result. Also included in each assay was a normal control pool sample derived from 20 healthy subjects and stored in aliquots at -20°. By measuring the amount of '25I-PF4 without added antibody, the patient samples and all dilutions showed nonimmune precipitations of 2.4-4.0% of total counts. Results were calculated as percent inhibition IAbbreviations used in this paper: HETE, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid; HHT, 12L-hydroxy-5,8,10-heptadecatrienoic acid; PF4, platelet factor 4; SDS, sodium dodecyl sulfate; TSP, thrombin sensitive protein.
of binding. The sample without added PF4 (the zero point) represented -100% binding. Log percentage of inhibition was plotted against log PF4 concentration in the standard; the unknown samples were calculated as percent inhibition of binding and results read from the standard curve.
Secretion of serotonin and thrombin-sensitive protein.
Platelets were labeled with [14C]serotonin by adding the radioactive serotonin (0.45 ,uM final concentration) to the platelet-rich plasma and incubating the solution for 1 h at 180 with occasional agitation. After washing, the platelets were suspended to a concentration of 109/ml in ETS buffer (0.154 M sodium chloride, 0.01 M tris, and 1 mM EDTA, pH 7.4). We then added 1 U thrombin to 1-ml samples to initiate the secretion reaction and incubated the samples for 5 min at 370. The percentage of serotonin secreted was determined on centrifuged samples according to the method described by Massini and Luscher (31) . The secretion of thrombinsensitive protein was monitored by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis of both pellet and supernatant fractions.
SDS-polyacrylamide gel electrophoresis. Platelets were separated from platelet-rich plasma and washed by the method previously described (31) . The washed platelets were then suspended in ETS buffer. The washed platelets and the thrombin-induced secreted proteinis were solubilizedl in SDS by the procedure previously described (32) . These polypeptides were then separatecl by electrophoresis through a slab gel with a 5-20% exponential gradienit of acrylamide similar to the one originally described by Laemmnli (33) . The details used for obtaining electrophoretic separations of reduced samples have been reported previously (34) . The polypeptides in the gels were stained with Coomassie Blue. Surface glycoproteins were analyzed after lactoperoxidasecatalyzed iodination (33 showing a defect in a-granules in these platelets (13) Table I . Gray platelets contained fewer a-granulelike structures than controls (-10-15% of the control numbers). In addition, gray platelets contained an increased amount of surface-connected canalicular system compared with controls. The number of mitochondria and dense bodies in gray platelets were within the normal range for control platelets. The size of the gray platelets was increased with a mean platelet volume of 11.1 ,utm3 for patient R.K. compared with the normal range of 5.7-8.9 ,utm3. The platelets fromnM.P. were not sized quantitatively but, when viewed using the electron microscope, appeared large and identical to those of R.K.
Platelet serotontin, adenime nucleotides, lysosomFal entzymes, anid catalase. Measurement of platelet ATP and ADP were within normial limits, as were measurements of platelet serotonin (Table II) . Platelet lysosomal enzymes were meaisured only in R.K., with acid phosphaltase, 8-glucuronidase, and 8-N-acetylglucosaminidase, all well within the normnal range (±3 SD) wheni considlered in termns ofplatelet num-ber or platelet proteini (Table III) . Catalase activity was also normal in R.K., witlh a value of 8.8 U/mg platelet protein, and control values (n = 3) of 3.9-9.5 U/mg platelet protein.
Platelet fibrinogen, j3-thromboglobulin, PF4, and )latelet-derivec growcth factor. When compared with control levels of platelet fibrinogen (7.1 ,ug/10, platelets; range±3SD = 4.1-10.1), gray platelets were mlarkedlly decreased (R.K. = 0.6 ,ug/108 platelets; M.P. = 0.3 ,ug/108 platelets). Plasmiia fibrinogen levels (R.K. = 2,300 ,ug/ml, M.P. = 3,300 ,ug/ml) were not decreasedl (normiial range+3SD= 1,900-3,200 u.g/ml). Levels of the platelet-specific proteins 8-thromboglobtulin andl PF4 were very low wlheni measured in frozen-thawed p)latelet-rich plasmai Oron the release(d substance, after thrombin treatment of platelets (Table IV) . However, levels of these polypeptides in platelet-poor plasma were higher than normal. The platelet-derived growth factor ( Fig. 1) Polypeptide composition of normal and gray platelets. Fig. 2 shows the SDS electrophoresis ofthe polypeptides from the platelets of the two patients with the gray platelet syndrome. The gels of whole platelets (gels 1-3) showed that the gray platelets were markedly deficient in one polypeptide with a reduced apparent molecular weight of 185,000. Previous studies (35) have shown that this glycoprotein is a "thrombin sensitive protein" (TSP), a polypeptide described by Majerus and coworkers (36, 37) . Electrophoresis of these samples without reduction (disulfides intact) showed that this glycoprotein was of an apparent molecular weight of 400,000. TSP is released by thrombin stimulation of platelets (34) . Gels 7-9 show the polypeptides released from platelets after thrombin stimulation. The released material from control platelets (gel 7) clearly contains TSP as well as 8-thromboglobulin, PF4, and several other uncharacterized polypeptides. The SDS gel of the platelets obtained after thrombin stimulation in the same experiment (gel 4) revealed that most of the TSP had been secreted. The protein that remains in gel 4 in the region containing ,3-thromboglobulin and PF4 probably represents other platelet proteins of a similar molecular weight. Gels 2 and 3 of whole platelets from the two patients with the gray platelet syndrome show a marked deficiency in TSP in these patients. Some material is present in the region of the gel that contains PF4 and /-thromboglobulin, but this may in fact represent other platelet proteins of a similar molecular weight. The gels of the supernates of thrombin-treated gray platelets (gels 8 and 9) did not contain enough TSP, ,lthromboglobulin, or PF4 to stain on the acrylamide gel. The action of thrombin on the gray platelets was sufficient, however, to cause the secretion of serotonin as the amount platelets was peroxidase catalyzed iodination showed no major difelets. ferences from normial platelets (data not shown). is Usinlg lactoPlatelet aggregationi studies. Aggregationi of gray platelets induced by arachidonic acid and ristocetin was within normal limits (Table VI) . Platelet aggrega-5% MPDS+NPR tion in response to epinephrine was normal in R.K. and 10% MWBS slightly delayed in M.P. Aggregation in response to acid-soluble collagen and thrombin were consistently less than normal in both R.K. and M.P., as was ADP aggregationi. The abnormiial aggregation patterns have 5% MWBS been consistent over an 8-yr period for R.K. and a 2-yr period for NI.P. In addition to these agents, normiial aggregation with R.K. platelets was also observedc usinig phorbol myristate acetate (1 ,uM), polylysine (0.1 mg/ ml), polybrene (0.1 mg/miil) latex beads, an(d staphylo-
The present investigation has studied the biochemistry of gray platelets and found them to be selectively deficient in platelet fibrinogen, PF4, platelet-derived growth factor, fl-thromboglobulin, and TSP. Electron microscopic studies hadl previously shown that these platelets were selectively deficient in a-granules (13) . This deficiency has been confirmed and quantitated in II 12 13 14 the present report. Thus, our results provide important confirmation of earlier evidence using platelet subrial from normal cellular fractionation techniques and studies ofpatients th of fibroblast with combined deficiencies of a-granules and dense monkey whole bodies that had suggested that PF4, f3-thromboglobu- 2 3 4 5 6 7 8 9 FIGURE 2 SDS gels of platelets from control donors (gels 1, 4, and 7) and from two patients with the gray platelet syndrome (R.K. gels 2.5 and 8; M.P. gels 3, 6, and 9) . Washed platelets were solubilized by SDS and electrophoresed after reduction with f3-mercaptoethanol (gels [1] [2] [3] . Washed platelets were also treated with thrombin and removed from suspension by centrifugation. The platelets (gels [4] [5] [6] and supernatant fractions (gels [7] [8] [9] were solubilized by SDS and electrophoresed on the acrylamide gel. The positions of the labeled protein bands were identified either by comparison with pure proteins (PF4, f3thromboglobulin) or from earlier studies (34) . ABP, actin binding protein, I3TG, f3thrombo-globulin.
population. The a-granules can be seen to be completely distinct from dense granules, which were normal in both numbers and in their composition in the gray platelets studied. The a-granules are also distinct from lysosomes containing acid phosphatase, ,¢glucuronidase, and ,3-N-acetylglucosaminidase. The lysosomal granules were indistinguishable from the a-granules on routine electron microscopic studies; however, with special stains for acid phosphatase and aryl sulfatase, this granule population could be identified (13) and has been shown to be only a very small proportion of the a-granulelike structures in platelets. Thus, the number of lysosomes accounts for some of the a-granulelike structures seen in gray platelets (Table I) ; the finding of 10% of normal a-granules in gray platelets may, therefore, be on the high side of the actual figure. The normal value for catalase in gray platelets is consistent with the earlier findings that the gray platelets had normal numbers ofperoxisomes (13) , the organelle believed to contain platelet catalase.
One component deficient in gray platelets is TSP, a major glycoprotein of human platelets (32) . TSP is polymeric, consisting of disulfide-linked identical subunits. The nonreduced apparent molecular weight of this glycoprotein on SDS gels is -400,000-500,000, whereas the reduced apparent molecular weight is 185,000-190,000 (34, 35, 45) . The subcellular localization of TSP has been examined and been suggested to be associated with the a-granules (45) . When platelets are stimulated with thrombin or other agents, TSP is secreted with other macromolecules and the contents of the dense bodies (32, 46, 47) . The present results provide further evidence that TSP is located in the agranules, and gray platelets may eventually provide useful cells to evaluate the role of this glycoprotein in platelet function.
The fundamental importance of a-granules is uncertain. However, the degree of prolongation of the bleeding time in patient R.K., and the amount of susceptibility to bruising in both patients, suggests that the agranule or its contents does add to some extent to the platelet response in vivo. Certain functions of the gray platelets were normial, including aggregationi in response to arachidonic acid and ristocetini. Aggregationi in response to epinephrine and ADP showed the presence of both primary and secondary waves in samples of gray platelets, though a higher than usual concentration of ADP was necessary to achieve the ADP aggregation response. Aggregation in response to throm-bin and collagen was also decreased when comiipared with normal donors. This decrease was particularly marked in the case of thrombini. These findings suggest that the contents of a-granules exert a potentiating effect on normal platelet aggregationi in response to thrombin, collagen, and ADP. The low platelet numbers seen in patients with the gray platelet syndromne suggests either that these platelets are being destroyed more readily than normal platelets in the circulation or that megakaryocyte production is decreasecd. Alternatively, there may be an abnormality in separationi of platelets from inegakaryocytes similar to MIediterranean macrothrombocytosis with decreased numbers of large platelets representing a normiial platelet mass (48) .
The reason for the a-granule deficiency in these patients is not entirely clear, but certain findings are suggestive. The deficiency of many proteins at the same time suggests that the primary deficiency might be a regulator gene that governs synthesis of all agranule proteins, or in a granule membrane or phospholipid component responsible for binding or assembly. The apparent increase in the channels of the surface-connected canalicular system in gray platelets may be due to the presence of granules that are empty and therefore, appear to be channels of the surfacecoinnected canalicular system; this increase would be consistent with either possibility. The raised levels of PF4 and ,3-thromboglobulin found in the platelet-poor plasma of patients R.K. and M.P., relative to normals, suggests that the proteins are synthesized, supporting the concept that the (lefect is in the binding or assembly of these proteins inito granules. It is very unlikely that the a-grantule proteins are low in these patients solely because of' release in vivo during the circulation, because examination of the megakaryocytes fromn these patients has shown them to be deficient in a-granules similar to the platelets. Furthermore, the selective release of >90% of the platelet a-granule contents wlhile the dense bodies remain intact seems; unlikely without some underlying specific a-granule defect. A defect in assembly or binding of these proteins into the a-granules, therefore, seems most probable.
